Surgerii Robotics logo

Surgerii Robotics

Surgerii Robotics, based in Beijing, makes the SHURUI single-port surgical robot, approved in China in 2023 and CE marked in Europe in 2025, including for children. Its 2025 revenue was 81.3 million yuan, about 11 million dollars, in its STAR Market IPO prospectus.1,10

Robotics Reviewed Editorial TeamUpdated November 10, 2026surgerii.com

Our take

Surgerii's SHURUI robot runs three continuum-bending instruments and a flexible 3D endoscope through one incision of 2 to 4 cm, for urology, gynecology, general, thoracic, and pediatric surgery. The company says more than 3,500 procedures have been done with it.3,10

It suits hospitals that want single-port robotic surgery outside the da Vinci ecosystem, especially in Europe and China. It is still small and loss-making: 11 robots sold in 2025, and a net loss of 131.6 million yuan on 81.3 million yuan of revenue.10

Scores by criterion

Surgerii Robotics scores out of 10
Pricing transparency4.5
Product maturity6.5
Deployment evidence6.0
Company durability6.0
Ease of integration6.0
Overall score (average of the five)5.8

Pricing transparency, 4.5: There is no price list, but the prospectus discloses one real deal: a direct price of 2.42 million euros for the single-port robot project at Vall d'Hebron University Hospital in Spain in the first half of 2026. It also mentions leasing and pay-per-procedure deals abroad.10

Product maturity, 6.5: The SR-ENS-600 system won Chinese approval in June 2023 and CE marking in August 2025. The company calls it the second single-port surgical robot approved anywhere, and the only one CE marked for pediatric surgery at the end of 2025. Volume is still low, with 11 robots sold in 2025.10

Deployment evidence, 6.0: The company reports more than 3,500 procedures, more than 107 clinical centers, and more than 1,900 surgeons trained. Its European sites include Vall d'Hebron in Barcelona, Spain, and Munich Clinic Bogenhausen in Germany.10,1,6

Company durability, 6.0: Revenue rose from 18.6 million yuan in 2024 to 81.3 million yuan in 2025, but the net loss was 131.6 million yuan. Cash of 918.6 million yuan and a 6.4% debt ratio at the end of 2025 give it a cushion, and it has filed for a STAR Market listing.10

Ease of integration, 6.0: The robotic arms stay still while the surgeon moves the instruments and endoscope, which the company says reduces redocking and collision risk. In China it sells through distributors, and abroad it sells direct, with leasing and per-procedure options.4,10

Each criterion is defined on our methodology page.

Who uses Surgerii and what it's for

The buyer is a hospital surgery department, often in urology, gynecology, thoracic, or pediatric surgery, that wants single-port robotic procedures through a small incision.5,3

Buyers should compare it with Intuitive's da Vinci SP, Edge Medical, and CMR Surgical, which its prospectus covers as industry peers, plus SS Innovations and Distalmotion.10

SHURUI SP surgical system

The instruments use a patented dual continuum mechanism built from super-elastic nitinol rods, which bends along the shaft by up to 210 degrees instead of using articulated joints.4

The surgeon console gives stereoscopic 3D views with up to 10 times magnification and filters hand tremor.3

Deployments

In June 2026 Vall d'Hebron University Hospital in Barcelona, Spain, did the first European pediatric procedure with the system, and in September 2026 Munich Clinic Bogenhausen reported a world-first adrenalectomy approach with it.9,7

France's UniHA hospital purchasing group selected the system through a public procurement process in 2026, and the company lists 18 clinical centers in China on its site.8,6

Pricing

The company does not publish prices. The only public figure is the 2.42 million euro direct price for the Vall d'Hebron project in its prospectus. In Munich it installed the robot on a pay-per-procedure basis.10

Company, leadership, and revenue

Professor Kai Xu of Shanghai Jiao Tong University founded the company in 2014. He is chairman, general manager, and chief technology officer, and controls 43.61% of its voting rights.2,10

Revenue was 81.3 million yuan in 2025, about 11 million dollars at 7.2 yuan per dollar, up from 18.6 million yuan in 2024. Robots and related equipment made up 78% of 2025 main business revenue, and the company had 266 employees.10

Competitive landscape

Which of these companies scores best, and who is each one built for?Hover over or tap a logo for details.
Top rated, for smaller operationsTop rated, for large enterprisesLower score, for smaller operationsLower score, for large enterprisesNot yet reviewed45678910Review Score← Smaller operationsLarge enterprises →Who it's built for5.86.26.56.46.1
Surgerii Robotics and its competitors
CompanyProductPricing modelDeployment footprintWhere Surgerii wins or loses
Surgerii RoboticsSHURUI single-port robot with continuum-bending instruments3No list; one EUR 2.42M direct contract price disclosed10More than 3,500 procedures; 11 robots sold in 202510Single-port continuum robot; small volumes; loss-making in 2025
Intuitive (da Vinci)da Vinci multi-port and single-port surgical systems11Sales plus leases, many with usage-based payments11About 12,094 systems installed at September 30, 202611Intuitive wins on installed base and instruments. Surgerii wins on flexible continuum instruments and CE marking that covers children.
Edge MedicalMP1000 multi-port and SP1000 single-port robots13About RMB14.53M average tender price in China12100 robots installed or delivered, 54 overseas14Edge wins on scale, with both multi-port and single-port robots. Surgerii wins on flexible continuum instruments and CE marking that covers children.
CMR Surgical (Versius)Versius Plus modular surgical robot15Not published1545,000 cases worldwide; FDA 510(k) for gallbladder removal15CMR wins on modular carts in Europe. Surgerii wins on flexible continuum instruments and CE marking that covers children.
SS InnovationsSSi Mantra modular surgical robot16Less than a third of a da Vinci's price in a 2022 report17224 systems in twelve countries by June 30, 2026; not yet FDA cleared18,19SS Innovations wins on lowest system cost. Surgerii wins on flexible continuum instruments and CE marking that covers children.
Distalmotion (DEXTER)DEXTER soft-tissue surgical robot with a small, mobile footprint20Not published20Almost 3,000 patients treated; three US clearances20Distalmotion wins on open-console design. Surgerii wins on flexible continuum instruments and CE marking that covers children.

Limits

No published price list.10

Lost 131.6 million yuan in 2025.10

Only 11 robots sold in 2025.10

What customers say

Where it helps

Up to 10 times magnified 3D views through a single small incision.3

Where it falls short

Not yet profitable; it relies on cash from funding rounds.10

Leadership

Surgerii does not publish a leadership page with photos. Its About page credits founder Professor Kai Xu, and the prospectus lists him as chairman, general manager, and chief technology officer.2,10

    Sources

    1. Surgerii Robotics, SHURUI single-port surgical robot homepage, accessed November 10, 2026
    2. Surgerii Robotics, About, accessed November 10, 2026
    3. Surgerii Robotics, The SHURUI SP Surgical System, accessed November 10, 2026
    4. Surgerii Robotics, System principles, accessed November 10, 2026
    5. Surgerii Robotics, Clinical applications, accessed November 10, 2026
    6. Surgerii Robotics, Contact and clinical centers, accessed November 10, 2026
    7. Surgerii Robotics, A World First for SHURUI Single-Port Robotic Surgery (September 7, 2026), accessed November 10, 2026
    8. Surgerii Robotics, A new milestone for SHURUI in France (September 9, 2026), accessed November 10, 2026
    9. Surgerii Robotics, First European Pediatric Single-Port Robotic Surgery (June 19, 2026), accessed November 10, 2026
    10. Beijing Surgerii Robotics, STAR Market IPO prospectus, application draft (Shanghai Stock Exchange, June 29, 2026), accessed November 10, 2026
    11. Intuitive Surgical, Form 10-Q for the quarter ended September 30, 2026, accessed November 1, 2026
    12. MedChina, 2025 tender report, accessed November 9, 2026
    13. Edge Medical, Homepage, accessed November 9, 2026
    14. VCBeat, China-made surgical robots, accessed November 9, 2026
    15. CMR Surgical, Home page, accessed November 1, 2026
    16. SS Innovations, Investor overview, accessed November 1, 2026
    17. Business Standard, SSI Mantra costs one-third of global price, September 15, 2022, accessed November 1, 2026
    18. SS Innovations, Second quarter 2026 financial results, August 13, 2026, accessed October 31, 2026
    19. SS Innovations, Response to FDA request for additional information on the SSi Mantra 510(k), October 13, 2026, accessed October 31, 2026
    20. Distalmotion, Distalmotion raises $150 million, November 18, 2025, accessed November 1, 2026